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Background: Advanced-stage mycosis fungoides (MF)/Sézary syndrome (SS) patients are weighted by an unfavorable
prognosis and share an unmet clinical need of effective treatments. International guidelines are available detailing treatment
options for the different stages but without recommending treatments in any particular order due to lack of comparative trials.
The aims of this second CLIC study were to retrospectively analyze the pattern of care worldwide for advanced-stage MF/SS
patients, the distribution of treatments according to geographical areas (USA versus non-USA), and whether the heterogeneity
of approaches has potential impact on survival.
Patients and methods: This study included 853 patients from 21 specialist centers (14 European, 4 USA, 1 each Australian,
Brazilian, and Japanese).
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Results: Heterogeneity of treatment approaches was found, with up to 24 different modalities or combinations used as
first-line and 36% of patients receiving four or more treatments. Stage IIB disease was most frequently treated by total-skin-
electron-beam radiotherapy, bexarotene and gemcitabine; erythrodermic and SS patients by extracorporeal
photochemotherapy, and stage IVA2 by polychemotherapy. Significant differences were found between USA and non-USA
centers, with bexarotene, photopheresis and histone deacetylase inhibitors most frequently prescribed for first-line treatment in
USA while phototherapy, interferon, chlorambucil and gemcitabine in non-USA centers. These differences did not significantly
impact on survival. However, when considering death and therapy change as competing risk events and the impact of first
treatment line on both events, both monochemotherapy (SHR¼ 2.07) and polychemotherapy (SHR¼ 1.69) showed elevated
relative risks.
Conclusion: This large multicenter retrospective study shows that there exist a large treatment heterogeneity in advanced MF/
SS and differences between USA and non-USA centers but these were not related to survival, while our data reveal that
chemotherapy as first treatment is associated with a higher risk of death and/or change of therapy and thus other therapeutic
options should be preferable as first treatment approach.
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Introduction
Patients with advanced-stage mycosis fungoides (MF)/Sézary
syndrome (SS) are characterized by skin tumours (stage IIB) or
erythroderma (stage III); blood (stage IVA1), nodal (stage IVA2)
or visceral involvement (stage IVB) may occur [1–5]. The prog-
nosis of advanced-stage disease is poor, with 5-year overall
survival (OS) rates from 40% to 70% in tumor-stage or
erythroderma, down to 15%–40% for extracutaneous involve-
ment [6–10]. Thus, these patients have an unmet clinical need of
effective treatments. However, the rarity of the disease and the
lack, until recently, of established criteria for staging and response
evaluation [11] impaired the development of prospective clinical
trials and no treatments have been shown to improve survival.
International guidelines detail treatment options for the different
stages without recommending any treatment order due to lack of
comparative trials [12–15]. The current therapeutic strategies in
leading centers worldwide have been influenced therefore by con-
sensus and institutional preference, geographical regulatory sta-
tus and availability of treatment modalities. No data are available
as to therapy heterogeneity across the world, and what impact
(if any) this variability may have on survival.
In 2012, members from the Cutaneous Lymphoma Task Force
(CLTF) of the European Organization for Research and
Treatment of Cancer (EORTC), the International Society for
Cutaneous Lymphoma (ISCL) and the United Cutaneous
Lymphoma Consortium (USCLC) established the Cutaneous
Lymphoma International Consortium (CLIC), with the aim of
developing collaborative researches, producing meaningful pro-
spective studies and improving the understanding of CTCL clin-
ical and biological characteristics. As first collaborative step,
retrospective studies were undertaken to test the potential of col-
lecting large clinical data sets. The first CLIC project analyzed
prognostic markers on OS in 1394 advanced-stage MF/SS pa-
tients [16], identifying as independent unfavorable variables stage
IV, age>60 years, large-cell transformation and increased LDH
values and combining them in a prognostic index model (low-,
intermediate- and high-risk group). As a second step, the partici-
pating centers were asked to provide treatment modalities for
advanced-stage MF/SS patients. The aims of this second CLIC
study, reported in this paper, were to analyze the global pattern
of care worldwide, the distribution of treatments according to
geographical areas (USA versus non-USA) and whether the het-
erogeneity of approaches can have potential impact on OS.
Patients and methods
Patient selection
Patients were collected retrospectively from 21 international centers (14
European, 4 USA, 1 Australian, Brazilian, and Japanese). Inclusion crite-
ria were: diagnosis from January 2007 to December 2014, clinical stage
IIB or higher [5] (Table 1).
MF diagnosis was confirmed according to ISCL/EORTC criteria [2–5].
All the patients were re-classified according to the new ISCL/EORTC classi-
fication [2–5, 17]. All patients had a detailed physical exam for the deter-
mination of the extent and severity of skin involvement and imaging study
to assess nodal or visceral disease. The pathologic diagnosis was based on
the biopsy results reported by institution hospital registries. Nodal/visceral
involvement was defined in the presence of pathological confirmation.
Data collected
Data retrieved for each patient were: demographics, TNMB staging at ini-
tial diagnosis of advanced-stage disease, treatment modalities up to the
10th treatment line whenever performed, total number of treatment lines,
start and end date for each treatment; survival status at last contact; date
of death or of last contact for patients alive. Treatment response data
were not collected due to the absence of homogeneous response evalu-
ation criteria and difficulties to define retrospectively response according
to the recent consensus criteria [11].
Statistical analysis
Continuous variable distributions were compared through the Wilcoxon
rank-sum test. The possibility of an association between categorical vari-
ables was assessed through the Fisher’s exact test. The non-parametric
test for trend across ordered groups developed by Cuzick [18] was used
to compute the test for trend for the prevalence of use of different treat-
ments in consecutive therapy lines. A logistic regression model was fitted
to data with the type of treatment as the outcome and geographical area
(USA/non-USA), stage (categorical variables with six levels: IIB, IIIA,
IIIB, IVA1, IVA2, IVB), and age at diagnosis as predictors.
Overall survival (OS) was established from diagnosis to death or to the
last contact date or to the end of follow-up, whichever occurred first,
counting all deaths as events. Life-table survival estimates were derived
by the Kaplan–Meier method by age, TNMB stage and geographical site,
and compared using the Mantel’s stratified log-rank test [19]. A
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multivariable Cox proportional-hazards regression model was used to es-
timate the association between mortality for all causes and the variables
above [20]. The proportionality assumption was assessed by examination
of Schoenfeld residuals, giving no reason for violation.
In order to investigate the effects of the first treatment line, we estimated the
cumulative mortality curves treating the change of therapy class as a competing
risk event. Cumulative incidence of both therapy change and death by age,
TNMB stage, geographical site and first treatment line were compared using a
multivariable competing risk regression model for the sub-distribution hazards
fitted to data according to the method of Fine and Gray [21].




Among 853 patients included, 40.4% were from USA centers,
with the majority of the remaining from Europe. Median follow-
up time was 1.7 years. Less than one-third of patients (29%) were
followed for <1 year, whereas 43% and 27% were followed for at
least 2 or 3 years, respectively.
There was a male preponderance (male/female: 1.61) with a me-
dian age at advanced-stage diagnosis of 64 years (range: 8–90), with-
out differences between USA and non-USA centers. Stage IIB was the
most frequent at first diagnosis of advanced-stage disease (35.4%).
There was a higher percentage of stage III in non-USA centers, while
stage IVB was more frequently in USA (P< 0.001) (Table 2).
Treatment lines
The median number of treatment lines was two per patient in
both USA and non-USA centers, with a remarkable number of
patients receiving multiple treatments (36% 4 or more; 2% be-
tween 10 and 24).
Table 3 shows the distribution of treatments in time. The most
commonly used first approach was photopheresis either alone
(10%) or in combination (8.6%), followed by bexarotene and
phototherapy. The most frequently used chemotherapies as first-
line treatment were gemcitabine (6.2%) and polychemotherapy
(5.3%). Photopheresis was the most frequently used approach
also as second-line treatment, while as third line, bexarotene and
interferon (IFN) were most widely employed. From the fourth
treatment line, histone deacetylase inhibitors (HDACi), polyche-
motherapy and pegylated doxorubicin were more commonly
prescribed. Allogeneic transplantation was not performed in any
case as first treatment, but it was most common from the fourth
line of treatment (from 4.2% to 6.4% of patients) (test for trend
with treatment line: P< 0.0001).
In summary, a statistically significant decrease of use with the
number of treatment lines was found for photopheresis, bexaro-
tene and phototherapy, while there was an increase with lines of
therapy for poly-chemotherapy, TSEBT, HDACi, pegylated
doxorubicin, new target therapies and transplantation (supple-
mentary Figures S1 and S2, available at Annals of Oncology
online).
Treatment approaches according to stages
The most frequently used first-line treatment in stage IIB patients
was bexarotene followed by local RT, phototherapy, TSEBT and
gemcitabine (supplementary Table S1, available at Annals of
Oncology online). Methotrexate was the most commonly used
first treatment for stage IIIA, while photopheresis (alone or in
combination) for stage IIIB. Photopheresis was also the most
common first-line treatment in stage IVA1 followed by IFN and
Table 1. Participating centers and number of patients included
Principal investigator Center Patient number Geographical area
Julia Scarisbrick University Hospital Birmingham, UK 35 Europe
Pietro Quaglino University of Turin (Torino), Italy 50 Europe
Maarten Vermeer Leiden University Medical Centre, The Netherlands 54 Europe
Evangelia Papadavid Athens University Medical School, Greece 40 Europe
Pablo Oritz-Romero Hospital 12 de Octubre, Madrid, Spain 23 Europe
Martine Bagot Hospital St Louis, Paris, France 49 Europe
Rudolf Stadler Unit Univ Munster, Minden, Germany 11 Europe
Pier Luigi Zinzani Seragnoli Institute of Haematology, Bologna, Italy 4 Europe
Nicola Pimpinelli University of Florence, Italy 22 Europe
Octavio Servitje Hospital Universatari de Bellvitge, Barcelona, Spain 15 Europe
Emilia Hodak Rabin Medical Center, Israel 30 Europe
Alessandro Pileri Dermatologic Clinic, University of Bologna, Italy 14 Europe
Teresa Estrach Hospital Clinico, University of Barcelona 13 Europe
Emilio Berti University of Milano, Italy 28 Europe
Youn Kim Stanford University Medical Centre, California, USA 123 USA
Joan Guitart Northwestern Univesity, Chicago, USA 47 USA
Madeleine Duvic MD Anderson Cancer Centre, Houston, USA 169 USA
Pierluigi Porcu Ohio State University, Ohio, USA 6 USA
Miles Prince Peter MacCallum Cancer Centre East Melbourne 58 Australia
Makato Sugaya Faculty of Medicine, University of Tokyo, Japan 29 Japan
José Antonio Sanches University of Sao Paulo Medical School, Brazil 33 Brazil
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chlorambucil, while stage IVA2 was mainly treated by poly-
chemotherapy as first approach.
First treatment line distribution according to stage,
age and geographical site
Figure 1 summarizes first-line treatments used in USA and non-
USA centers, while Table 4 shows the odds ratio (OR) of receiving
a given first-line treatment according to disease stage, age and
geographical site. Phototherapy, alone or in combination, is used
less frequently in USA. Photopheresis and bexarotene are signifi-
cantly associated with the geographical area, being more frequent
in USA while IFN, which does not show a statistically significant
association with stage, was more frequently prescribed in non-
USA centers. HDACi were used in all stages but, as expected,
more frequently in USA (FDA approval), while MTX was used
predominantly in stage III, without differences between USA and
non-USA centers. Compared with USA centers, non-USA centers
treat their patients significantly more frequently with chlorambu-
cil also more frequently adopted in elderly patients. No differ-
ences were found in poly-CT or pegylated doxorubicin according
to geographical areas.
Survival analyses
Two types of analysis were carried out (Figure 2 and Table 5). In
the first, the variables age, TNMB stage and geographical site
(USA versus non-USA) were included in a Cox regression model,
with death due to any cause as the end point. Age and stage
showed prognostic significance while geographical site did not
show any association with mortality.
In the second analysis, death and therapy change were con-
sidered as competing risk events, and the impact of first treatment
line on both events was analyzed with a Fine and Gray regression
model. Geographical site and stage did not show any prognostic
relevance for either outcome, whereas the only statistical signifi-
cant association was between age and death. Although overall
first-line treatment group was not selected as independent prog-
nostic variable, both mono-chemotherapy (SHR¼ 2.07, 95% CI
1.14–3.78) and poly-chemotherapy (SHR¼ 1.69, 95% CI 0.61–
4.66) showed elevated relative risks of death.
Discussion
In this second CLIC study, the largest cohort of patients present-
ing with advanced-stage MF/SS (853 cases) with data on treat-
ment collected retrospectively in 21 international centers was
analyzed to evaluate the worldwide usage profile of regionally
available treatments and potential impact on survival.
The first finding was that treatment approaches are character-
ized worldwide by a striking heterogeneity with up to 24 different
drugs, modalities or combinations used as first-line treatment.
Several explanations can lead to this heterogeneity, mainly repre-
sented by the rarity of the disease, which impaired the design of
randomized clinical trials and thus the development of homoge-
neous treatment guidelines, and additionally the limited activity
of available drugs [15]. This opened the field for treatment algo-
rithms based on institutional preference, skill and equipment of
Table 2. Demographics, staging and number of treatment lines
Parameter All (%) USA (%) Non-USA (%) P
Gender
Male 466 (54.6%) 213 (61.7%) 253 (49.8%) 1.000 (exact Fisher’s test)
Female 289 (33.9%) 132 (38.3%) 157 (30.9%)
Missing 98 (11.5%) 98 (19.3%)
Total 853 345 508
Agea
Median 64 63 64 0.7466 (Wilcoxon rank-sum test)
Range 8–90 11–90 8–90
Clinical stageb
IIB 309 137 (39.7%) 172 (33.9%) <0.001 (exact Fisher’s test)
IIIA 117 31 (9.0%) 86 (16.9%)
IIIB 73 13 (3.8%) 60 (11.8%)
IVA1 224 88 (25.5%) 136 (26.8%)
IVA2 74 40 (11.6%) 34 (6.7%)
IVB 27 15 (4.4%) 12 (2.4%)
Missing 29 21 (6.1%) 8 (1.6%)
Total 853 345 508
Number of treatment lines
Median 2 2 2 0.045 (Wilcoxon rank-sum test)
Range 1–24 1–24 1–15
aAt diagnosis of advanced phase MF/SS.
bAccording to the revised TNMB classification [x].
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each institute, different regulatory status, availability of treatment
modalities, entry to clinical trials and health insurance system. In
the future, the identification of new clinical and biological prog-
nostic parameters may help to drive clinical treatment decisions
[16, 22]. Disease stage clearly remains an important parameter
for treatment decision and TNMB stage was associated with rele-
vant differences in treatment approaches, as expected [12–14].
Stage IIB was most frequently treated by skin-directed
approaches (phototherapy or radiotherapy), bexarotene and
gemcitabine while photopheresis was most commonly used as
first-line treatment in SS or erythrodermic MF (stage III and
IVA1) and polychemotherapy in stage IVA2/B. There were trends
in drug use during the course of the disease with decreased use of
photopheresis alone or in combination, bexarotene and photo-
therapy alone or in combination and conversely, increased use of
chemotherapy, target therapies and transplant. These data sup-
port a preferential use of immune-modifiers as first line therapy
with subsequent use of chemotherapy, targeted therapies or
transplant for patients with relapsed/resistant disease. This strat-
egy of using immune-stimulation is solidly based on pre-clinical
data, showing the relevance of cancer immuno-surveillance in
down-regulating the evolution of the disease [23], now supported
by a number of clinical studies [24] such as the superior outcome
of photopheresis when performed as first-line treatment early
after diagnosis [25]. The USCLC recommendations [26] high-
light that one of the principles for SS treatment is to preserve the
immune response, fostering the use of immune-modulatory ther-
apy (particularly as combination therapy) before chemotherapy
except in the presence of rapid growth of tumor burden or failure
of prior such therapies.
The second focus was that there exist significant differences in
treatment approaches between USA and non-USA centers. The
therapies more frequently prescribed as first-line treatment inde-
pendent of disease stage distribution are bexarotene and photo-
pheresis in USA while phototherapy, IFN, chlorambucil and
gemcitabine for non-USA centers. The same factors that ac-
counted for treatment heterogeneity can partly explain these geo-
graphical differences, mirroring different approaches to patient
management along with different drug regulatory approvals
(HDACi and denileukin diftitox not available outside the USA)
and access to new drugs through clinical trials. The major use of
photopheresis in USA and gemcitabine in non-USA centers can
Table 3. Distribution of treatments performed in time (percentage of patients treated with that therapy out of the total no. of patients treated in a given
treatment line) in the first 10 treatment lines
Therapy 1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th P for trend
ECP (alone or in combination) 18.6 13.3 6.3 5.8 6.4 4.8 2.8 7.7 9.4 5.3 0.952
Bexarotene 11.3 12.8 10.3 7.4 7.4 5.6 4.2 1.9 6.3 10.5 0.001
Phototherapy (alone or in combination) 9.5 5.9 3.5 3.4 3.5 2.4 2.8 1.9 5.3 0.949
Methotrexate 8.8 5.9 7.0 6.8 4.5 9.6 6.9 9.6 6.3 10.5 0.232
Interferon 7.7 7.7 10.8 8.5 8.4 4.8 5.6 1.9 3.1 5.3 0.616
Local RT 7.3 5.7 7.0 5.1 5.0 8.0 6.9 7.7 6.3 5.3 0.442
Gemcitabine 6.2 5.6 6.8 6.1 4.0 8.8 1.4 1.9 0.378
Polychemotherapy 5.3 9.2 9.8 9.8 10.4 10.4 16.7 13.5 9.4 26.3 <0.0001
TSEBT 4.5 7.9 7.0 5.7 9.4 6.4 6.9 9.6 6.3 5.3 0.028
Chlorambucil 3.6 2.5 2.1 2.7 2.0 1.6 1.9 0.067
HDACi 2.9 5.6 5.4 12.5 5.5 8.8 11.1 1.9 9.4 <0.0001
Other Retinoids 2.7 2.7 1.9 1.0 1.4 3.1 0.029
Pegylated Doxorubicin 1.8 4.7 4.4 3.7 10.9 4.8 5.6 5.8 12.5 5.3 <0.0001
Alemtuzumab 1.3 2.9 3.5 3.4 2.0 2.4 5.6 1.9 3.1 15.8 0.006
Interferon plus Bexarotene or Other Retinoids 0.8 0.5 0.7 0.3 0.020
Other Monochemotherapy 0.7 1.7 2.1 2.0 3.0 3.2 5.6 5.8 6.3 <0.0001
Denileukin Diftitox 0.5 0.3 0.7 0.7 1.0 1.4 3.9 6.3 0.008
Brentuximab vedotin 0.4 0.7 4.0 2.4 3.0 5.6 5.6 1.9 <0.0001
Pralatrexate 0.2 0.8 1.4 2.0 1.0 1.6 1.4 5.8 3.1 <0.0001
Topical Nitrogen Mustard (Mechlorethamine) 0.1 0.2 0.5 1.6 1.9 0.001
Bevacizumab 0.5 –
Lenalidomide 0.7 1.5 –
Mogamulizumab 1.2 0.9 2.4 2.5 2.4 2.8 5.8 3.1 <0.0001
Transplantation 1.0 2.3 6.4 6.4 4.8 4.2 5.8 6.3 5.3 <0.0001
Zanolimumab 0.2 0.2 0.3 1.9 0.003
Other retinoids: etretinate, acitretin. Other monochemotherapy: mainly cyclophosphamide, etoposide. First treatment unknown in 5.6% of patients. ECP
combos: ECP plus Interferon, ECP plus Bexarotene, ECP plus Other Retinoids, ECP plus IFN plus Bexarotene, ECP plus Methotrexate, ECP plus Phototherapy.
Phototherapy combos: Phototherapy plus IFN, Phototherapy plus Other Retinoids, Phototherapy plus Bexarotene, ECP plus Phototherapy, Phototherapy
plus IFN plus Bexarotene, Phototherapy plus Other Retinoids.
ECP, extracorporeal photochemotherapy; RT, radiotherapy; TSEBT, total-skin-electron-beam therapy; HDAC, histone deacetylase inhibitors.
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Figure 1. Distribution of first treatment line between USA and non-USA centers.
Table 4. Association (OR: odds ratio) between treatments, stage and age at diagnosis, and geographical region (USA versus non-USA)
OR Stage (ref: stage IIB) P USA P Age P
IIIA IIIB IVA1 IVA2 IVB (ref: non-USA)
ECP (alone or in combination) 12.01 25.36 24.79 4.84 13.17 <0.001 2.46 <0.001 1.02 0.026
Bexarotene 0.51 0.45 0.26 0.59 0.59 0.005 1.83 0.013 1.00 0.830
Phototherapy (alone or in combination) 1.11 0.65 0.61 0.98 NA 0.630 0.27 <0.001 0.99 0.135
Methotrexate 3.65 2.45 1.34 1.44 1.42 0.024 0.83 0.506 1.01 0.382
Interferon 0.86 1.11 2.61 2.69 1.16 0.063 0.31 0.001 0.96 <0.001
Local RT NA 0.19 0.08 0.07 0.18 <0.001 0.82 0.481 1.00 0.771
Gemcitabine 0.89 0.23 0.25 0.46 0.78 0.030 0.55 0.064 1.01 0.504
Polychemotherapy 0.91 1.63 0.78 4.54 2.40 0.009 0.89 0.746 0.98 0.181
TSEBT NA NA 0.07 0.35 0.28 0.002 1.74 0.136 1.03 0.018
Chlorambucil 5.08 6.43 17.23 5.11 54.83 0.005 0.04 0.002 1.04 0.029
HDAC inhibitors 1.20 2.84 1.45 2.74 NA 0.481 14.47 <0.001 0.98 0.151
Other Retinoids 1.77 0.80 1.52 0.70 NA 0.852 1.18 0.741 0.98 0.243
Pegylated Doxorubicin 1.35 1.30 0.18 0.50 NA 0.453 1.59 0.389 0.99 0.404
Interferon plus Bexarotene or Other Retinoids 0.76 1.01 2.45 2.31 1.03 0.071 0.36 0.002 0.96 <0.001
ECP, extracorporeal photochemotherapy; RT, radiotherapy; TSEBT, total-skin-electron-beam therapy; HDAC, histone deacetylase inhibitors.
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be driven by the fact that these treatments were originally trialed
in USA and Europe, respectively [27–29]. In USA there were few
centers with large volumes while Europe is characterized by many
centers each contributing a small number of patients, suggesting
a considerable effect of institution ‘tradition’. This could explain
the preferential use of unexpected drugs such as chlorambucil.
The major use of phototherapy outside USA could be related to
climate condition with reduced sun exposure in northern Europe
countries.
The final observation is that the differences in treatment
approaches as first-line therapy between USA and non-USA cen-
ters did not lead to a statistically significant impact on survival.
Indeed, stage and age were independent OS predictors while the
geographical site (USA versus non-USA) was not. The key out-
comes of the competing risk event approach (Fine and Gray
model) were that patients initially treated with polychemother-
apy are those that most frequently change therapy; even if overall
first-line treatment group was not selected as independent prog-
nostic variable for mortality of therapy change, both monoche-
motherapy (SHR¼ 2.07) and polychemotherapy (SHR¼ 1.69)
showed elevated relative risks of death, showing a negative impact
of chemotherapy on disease course when performed as first line
therapy. These estimates are adjusted for stage and geographical
site but cannot address the potential confounder of tumor bulk
or biology which is not adequately reflected by stage.
Interpretation of these findings should be taken in the context
that no chemotherapy regimen has been shown to improve sur-
vival given their modest clinical activity, with responses usually of
short duration (6–9 months) [12–14, 30, 31]. Moreover, it has
been reported that time-to-next-treatment [15] is significantly
shorter for single- or multi-agent chemotherapy (median:
3.9 months) with respect to interferon (8.7 months) and HDACi
(4.5 months). The results of the present study suggest that
chemotherapy should be reserved only after failure of previous
approaches and where other options are exhausted.
The main limitation of this study lies in its retrospective collec-
tion of information. Missing data and insufficient information to
avoid confounding by indication (estimate the effects of treat-
ments on prognosis not accounting properly for stage and disease
status, which in turn are determinant of the treatment and
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Figure 2. (A) Overall survival estimated with Kaplan Meier curves by age, stage and geographical areas. P values for log-rank tests are shown.
(B) Cumulative incidence curves for death and change of therapy considered as competing risk events by first treatment line. P values for
Fine and Gray test are shown. For survival analyses, treatment approaches were grouped into six categories defined after consensus within
the participating centers: (1) Skin-directed therapies: phototherapy, local radiotherapy, total-skin electron beam therapy (TSEBT), topical nitro-
gen mustard; (2) Systemic immune modulators and pro-apoptotic inducers: interferon (IFN), retinoids, bexarotene, extracorporeal photoche-
motherapy (photopheresis), low-dose methotrexate, lenalidomide, combinations with phototherapy plus retinoids and/or IFN; any
combinations of photopheresis plus retinoids and/or IFN; (3) Single agent chemotherapy: chlorambucil, gemcitabine, pegylated doxorubi-
cine, pralatrexate, other mono-chemotherapy; (4) Polychemotherapy: CHOP, CHOP-like, other poly-chemotherapy; (5) Targeted therapies:
denileukin diftitox, histone deacetylase inhibitors (HDACi), alemtuzumab, mogamulizumab, zanolimumab, brentuximab vedotin, bevacizu-
mab); (6) Autologous or allogeneic stem-cell or bone marrow transplantation.
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prognosis) must be kept in mind to avoid over interpretation.
Moreover, the absence of data maintained consistently and dif-
ferences in response tools and criteria, did not allow us to provide
response duration or quality of life information.
In conclusion, this large multicenter retrospective study shows a
substantial heterogeneity of treatment approaches in advanced
MF/SS between USA and non-USA centers, even if these differ-
ences do not influence survival outcome. The sequence of treat-
ments could play a role since we observed that chemotherapy,
when used as first treatment, is associated with a higher risk of
death and/or change of therapy. This retrospective study high-
lighted the importance of currently ongoing prospective CLIC
studies which will attempt to link treatment data with the prognos-
tic models such as those developed in the first CLIC study [16].
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